CDKN2A and cancer: More explicitly, patients with HPVDNA−/p16+ TSCC/BOTSCC had a better OS and DFS compared to patients with HPVDNA−/p16− cancer (log rank test: p = 0.001 and p = 0.05, respectively), but a worse OS compared to patients with HPVDNA+/p16+ cancer (OS: log rank test: p = 0.047), and the trend was similar for DFS (log rank test: p = 0.1).